Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price lifted by TD Cowen from $157.00 to $160.00 in a research report sent to investors on Monday, Benzinga reports. TD Cowen currently has a buy rating on the biotechnology company’s stock.
A number of other research firms also recently commented on ASND. JPMorgan Chase & Co. dropped their target price on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, September 4th. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Wells Fargo & Company upped their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $195.92.
Read Our Latest Stock Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Trading Up 1.7 %
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Equities research analysts expect that Ascendis Pharma A/S will post -7.2 EPS for the current fiscal year.
Institutional Trading of Ascendis Pharma A/S
A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Ascendis Pharma A/S by 14.3% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 7,034 shares of the biotechnology company’s stock worth $1,063,000 after purchasing an additional 882 shares during the last quarter. Private Ocean LLC acquired a new stake in Ascendis Pharma A/S during the 1st quarter valued at approximately $36,000. Matisse Capital grew its position in shares of Ascendis Pharma A/S by 2.6% during the 1st quarter. Matisse Capital now owns 35,540 shares of the biotechnology company’s stock worth $5,373,000 after buying an additional 905 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Ascendis Pharma A/S by 4,231.4% during the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock worth $11,419,000 after buying an additional 73,796 shares during the period.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- Most Volatile Stocks, What Investors Need to Know
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- The How And Why of Investing in Oil Stocks
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.